Therapeutic Advances in Neurological Disorders

Scope & Guideline

Exploring groundbreaking research in neurology.

Introduction

Explore the comprehensive scope of Therapeutic Advances in Neurological Disorders through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore Therapeutic Advances in Neurological Disorders in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN1756-2856
PublisherSAGE PUBLICATIONS LTD
Support Open AccessYes
CountryUnited Kingdom
TypeJournal
Convergefrom 2008 to 2024
AbbreviationTHER ADV NEUROL DISO / Ther. Adv. Neurol. Disord.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND

Aims and Scopes

The journal 'Therapeutic Advances in Neurological Disorders' focuses on advancing the understanding and treatment of neurological disorders through innovative research, clinical studies, and reviews. Its aims and scopes are characterized by a multidisciplinary approach that encompasses various facets of neurology, from basic science to clinical applications.
  1. Neurological Disorders Research:
    The journal emphasizes research related to a wide range of neurological disorders, including multiple sclerosis, Parkinson's disease, epilepsy, and neuromuscular disorders. It aims to provide insights into the pathophysiology, diagnosis, and treatment of these conditions.
  2. Clinical Trials and Efficacy Studies:
    A significant focus is on clinical trials evaluating the efficacy and safety of therapeutic interventions. The journal publishes systematic reviews and meta-analyses that synthesize evidence from clinical studies to guide treatment decisions.
  3. Innovative Therapeutic Approaches:
    The journal explores novel therapeutic strategies, including pharmacological treatments, immunotherapies, and emerging technologies such as gene therapy and neurostimulation techniques.
  4. Multidisciplinary Collaboration:
    There is a strong emphasis on collaboration among various specialties within neurology, combining insights from clinical practice, basic research, and patient-centered care to advance treatment paradigms.
  5. Patient-Centric Research:
    The journal prioritizes studies that consider patient perspectives, treatment adherence, and quality of life, reflecting a commitment to improving patient outcomes in neurological disorders.
Recent publications in 'Therapeutic Advances in Neurological Disorders' highlight several emerging themes that reflect current trends in neurological research and clinical practice. These themes indicate a shift towards more innovative and patient-centered approaches to treatment.
  1. Precision Medicine in Neurology:
    An increasing number of studies focus on precision medicine approaches, tailoring treatments based on individual patient characteristics such as genetic profiles and biomarkers. This trend is indicative of a broader movement towards personalized healthcare.
  2. Neuroinflammation and Immune Modulation:
    Research on neuroinflammation and its role in various neurological disorders is gaining prominence, with a focus on immune modulation therapies. This reflects a growing understanding of the immune system's impact on neurological health.
  3. Digital Health and Telemedicine:
    The integration of digital health technologies and telemedicine in managing neurological disorders is trending, particularly following the COVID-19 pandemic. Studies exploring the effectiveness of remote monitoring and treatment are becoming more common.
  4. Real-World Evidence and Patient Registries:
    There is a significant increase in the use of real-world evidence and patient registries to inform treatment patterns and outcomes. This trend emphasizes the importance of understanding how therapies perform in everyday clinical settings.
  5. Machine Learning and Artificial Intelligence:
    The application of machine learning and AI in predicting outcomes and personalizing treatment plans for neurological disorders is emerging as a significant area of research, reflecting the intersection of technology and medicine.

Declining or Waning

While 'Therapeutic Advances in Neurological Disorders' continues to evolve, certain themes have shown a decline in prominence in recent years. This waning focus may reflect shifts in clinical priorities, funding availability, or emerging areas of interest that have overshadowed older topics.
  1. Traditional Pharmacotherapy:
    There has been a noticeable decline in publications focusing solely on traditional pharmacotherapy for neurological disorders, possibly due to the increasing interest in novel therapies and personalized medicine.
  2. Basic Science Studies:
    Research articles centered exclusively on basic science without direct clinical implications have decreased, as the journal shifts toward more translational research that bridges laboratory findings with clinical applications.
  3. Single-Center Studies:
    The prevalence of single-center observational studies has waned, likely due to a preference for multi-center collaborations that enhance the generalizability of findings and provide a broader patient perspective.
  4. Historical Perspectives:
    There is less emphasis on historical reviews of treatments and practices in neurology, as the focus has moved towards current innovations and future directions in therapeutic approaches.
  5. Focus on Rare Disorders:
    The journal appears to have reduced its emphasis on rare neurological disorders, potentially due to the limited available research and funding compared to more prevalent conditions.

Similar Journals

Therapeutic Advances in Psychopharmacology

Advancing the Frontiers of Mental Health Treatment
Publisher: SAGE PUBLICATIONS LTDISSN: 2045-1253Frequency: 1 issue/year

Therapeutic Advances in Psychopharmacology is a leading open-access journal published by SAGE Publications Ltd, focusing on the dynamic integration of pharmacological therapies and psychological health. Since its inception in 2011, this journal has made a significant impact on the fields of pharmacology and psychiatry, consistently earning a Q1 ranking in both categories as of 2023, reflecting its esteemed position within the scientific community. With an impressive Scopus rank placing it in the top 15% across relevant disciplines, the journal serves as a vital platform for researchers, professionals, and students eager to explore cutting-edge advancements in psychopharmacology. The open-access model, established in 2019, ensures that groundbreaking research is accessible to a wide audience, fostering collaboration and innovation in therapeutic strategies for mental health disorders. Through the dissemination of high-quality research and reviews, Therapeutic Advances in Psychopharmacology is committed to advancing understanding and practice within this critical field.

Current Journal of Neurology

Fostering global insights in neurology and clinical care.
Publisher: TEHRAN UNIV MEDICAL SCIENCESISSN: 2717-011XFrequency: 4 issues/year

Current Journal of Neurology, published by Tehran University of Medical Sciences, is an esteemed Open Access journal dedicated to advancing the field of neurology. Since its inception in 2011, the journal has provided a platform for innovative research and critical discourse in neurology and clinical neurology, with a focus on the latest advancements and methodologies. Although the journal currently holds a Q4 quartile ranking in both neurology and clinical neurology, its goal is to foster the global dissemination of knowledge and ideas relevant to the complexities of neurological disorders. Researchers, professionals, and students exploring this dynamic field will find valuable insights, as the journal aims to bridge the gap between emerging research and clinical application. Based in Tehran, Iran, the Current Journal of Neurology welcomes contributions that enhance understanding and treatment of neurological conditions, thereby promoting evidence-based practices across the globe.

Degenerative Neurological and Neuromuscular Disease

Connecting researchers to combat degenerative disorders.
Publisher: DOVE MEDICAL PRESS LTDISSN: Frequency: 1 issue/year

Degenerative Neurological and Neuromuscular Disease is a distinguished academic journal published by DOVE MEDICAL PRESS LTD, focusing on the latest advancements in the field of neurology and neuromuscular disorders. With a commitment to disseminating high-quality research, the journal aims to provide a critical platform for researchers, healthcare professionals, and students to share and engage with groundbreaking studies that advance our understanding of degenerative conditions affecting the nervous system. Although the journal's impact factor and h-index are currently not available, its open access model ensures that the valuable findings published within are accessible to a global audience, thereby fostering collaboration and innovation in neurological health. The journal's address is PO BOX 300-008, Albany, Auckland 0752, New Zealand, reflecting its international relevance and commitment to advancing the field of neurology. As the understanding of neurodegenerative diseases and neuromuscular challenges continues to evolve, Degenerative Neurological and Neuromuscular Disease serves as an essential resource for anyone dedicated to improving patient outcomes and advancing scientific knowledge.

Physiotherapy

Advancing the Science of Rehabilitation
Publisher: ELSEVIER SCI LTDISSN: 0031-9406Frequency: 4 issues/year

Physiotherapy, published by Elsevier Science Ltd, stands as a prestigious journal in the field of Physical Therapy, Sports Therapy, and Rehabilitation. Since its inception in 1945, this journal has been committed to advancing the practice and science of physiotherapy through rigorous peer-reviewed research, making significant contributions to both clinical practice and academia. With an impressive Q1 ranking and a Scopus percentile of 88th, it is widely regarded as a leading source of evidence-based information for professionals and researchers alike. The journal operates without an Open Access option, which ensures that it maintains the quality and integrity of the research it publishes while providing exclusive access to valuable insights for its subscribers. By focusing on diverse topics within its scope, including therapeutic techniques, rehabilitation strategies, and sports medicine, Physiotherapy continues to shape the future of physiotherapy practice and education, making it an essential resource for anyone invested in this dynamic field.

Current Neuropharmacology

Pioneering insights in brain health and pharmacology.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1570-159XFrequency: 8 issues/year

Current Neuropharmacology is a premier journal dedicated to advancing the field of neuropharmacology, published by Bentham Science Publishers Ltd in the United Arab Emirates. As a leader in its domain, this journal has achieved a remarkable position in 2023, with Q1 rankings across several categories including Medicine (miscellaneous), Neurology, and Pharmacology. With a robust focus on the latest research related to pharmacological treatments and their neurological implications, Current Neuropharmacology features cutting-edge studies that inform clinical practices and psychiatric care. Although not open access, the journal offers both print and electronic formats to cater to a diverse audience of researchers, healthcare professionals, and students keen on accessing vital information in neuropharmacology. Its high impact within the academia is underscored by impressive Scopus rankings, confirming its importance as a vital resource for the ongoing exploration of mental health and neurotherapeutic innovations. With an engaging scope that encompasses emerging discoveries and clinical advancements, Current Neuropharmacology continues to be an essential platform for scholarly communication in the evolving landscape of neuroscience and pharmacology.

CNS DRUGS

Bridging Science and Practice in Neurological Care
Publisher: ADIS INT LTDISSN: 1172-7047Frequency: 12 issues/year

CNS DRUGS is a leading journal dedicated to the field of neuroscience, specifically focused on the advancement of pharmacological therapies for central nervous system disorders. Published by ADIS INT LTD, this esteemed journal has maintained a strong impact within its domain, achieving Q1 rankings in 2023 across multiple categories, including Neurology (clinical), Pharmacology (medical), and Psychiatry and Mental Health. With an impressive Scopus ranking as the 11th of 272 in medical pharmacology and high percentiles in psychiatry and neurology, it fosters high-quality research publication and dissemination. Spanning over two decades from 1994 to 2024, CNS DRUGS serves as a vital resource for researchers, professionals, and students alike, providing comprehensive insights that drive innovation in clinical practices. Although primarily a subscription-based journal, the richness of its content makes it an essential addition to any institution's library. Striving to bridge the gap between scientific research and clinical application, CNS DRUGS is positioned at the forefront of neurological and psychiatric pharmacotherapy research.

KLINISCHE NEUROPHYSIOLOGIE

Pioneering novel approaches in clinical neurophysiology.
Publisher: GEORG THIEME VERLAG KGISSN: 1434-0275Frequency: 4 issues/year

KLINISCHE NEUROPHYSIOLOGIE is a pivotal journal dedicated to advancing the field of clinical neurophysiology, published by GEORG THIEME VERLAG KG in Germany. With an ISSN of 1434-0275 and an E-ISSN of 1439-4081, this journal aims to disseminate high-quality research findings that enhance our understanding of neurological disorders and their physiological underpinnings. Although currently positioned in the fourth quartile in both Neurology (clinical) and Physiology (medical) categories, the journal offers a unique platform for novel insights and empirical studies, filling a crucial niche within the medical community. Researchers, healthcare professionals, and students can benefit from its Open Access option, which promotes wider accessibility and engagement with cutting-edge scientific discourse. As the journal converges through the years from 1998 to 2024, it remains committed to fostering scholarly collaboration and innovation in neurophysiological research, crucial for improving clinical outcomes.

Neurology International

Advancing Neurological Research for a Global Audience
Publisher: MDPIISSN: 2035-8377Frequency: 4 issues/year

Neurology International is a prestigious open-access journal published by MDPI that has been making significant contributions to the field of neurology since its establishment in 2009. With its ISSN 2035-8377, this journal is committed to disseminating high-quality, peer-reviewed research that addresses a wide range of clinical topics in neurology. Operating out of Basel, Switzerland, the journal holds a respectable Q2 ranking in the clinical neurology category as of 2023, indicating its influence and dedication to advancing scientific knowledge. Researchers and practitioners alike will find value in its comprehensive articles, which are readily accessible to a global audience, facilitating the sharing of innovative findings and clinical practices. As it converges towards 2024, Neurology International continues to provide a vital platform for scholarly discourse, aiming to improve patient outcomes and enhance our understanding of neurological disorders.

Neurology and Therapy

Advancing Neurological Health Through Open Access Research
Publisher: SPRINGER LONDON LTDISSN: 2193-8253Frequency: 2 issues/year

Neurology and Therapy, published by SPRINGER LONDON LTD, stands as a pivotal platform for researchers and practitioners in the field of neurology and its therapeutic applications. This Open Access journal, active since 2012, facilitates the dissemination of innovative studies and cutting-edge findings aimed at improving neurological health. With an impressive ranking in the 2023 Scopus Rankings, where it holds a Q2 category in Neurology and a Q1 category in Clinical Neurology, it underscores its prominence in advancing neurological research. The journal's intriguing scope encompasses a wide-ranging exploration of neurological disorders, treatment methodologies, and healthcare strategies, making it a valuable resource for those vested in enhancing patient outcomes. With an appealing average impact factor, readers are encouraged to dive into the latest advancements and engage with the scholarly discussions that are shaping the future of neurology.

ACTA NEUROLOGICA BELGICA

Exploring the Depths of Neurological Research.
Publisher: SPRINGER HEIDELBERGISSN: 0300-9009Frequency: 4 issues/year

ACTA NEUROLOGICA BELGICA is a leading academic journal published by Springer Heidelberg, dedicated to advancing the field of neurology and medicine. With an ISSN of 0300-9009 and E-ISSN 2240-2993, this journal has been a vital resource since its inception, contributing significantly to neurological research and clinical practice. It holds a respectable impact factor with categories spanning from Q2 in Medicine (miscellaneous) to Q3 in Neurology (clinical) as of 2023, indicating its prominence in the scientific community. The journal's extensive coverage since 1959 enhances its historical relevance, while its ongoing publication until 2024 ensures the latest developments are readily accessible. Researchers and practitioners can benefit from its rigorous peer-reviewed articles, which are crucial for staying current in this rapidly evolving discipline. As a scholarly platform, ACTA NEUROLOGICA BELGICA plays a pivotal role in disseminating knowledge and fostering innovation in neurology, making it a must-read for professionals, students, and anyone involved in the field.